Last reviewed · How we verify

Epogen — Competitive Intelligence Brief

Epogen (Epoetin Alfa-Epbx) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoiesis-stimulating agent (ESA). Area: Hematology.

marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor Hematology Live · refreshed every 30 min

Target snapshot

Epogen (Epoetin Alfa-Epbx) — Amgen. Epoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Epogen TARGET Epoetin Alfa-Epbx Amgen marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor 1989-01-01
Eporatio EPOETIN THETA marketed Erythropoietin receptor 2009-01-01
Mircera METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA Hoffman-La Roche marketed erythropoietin receptor 2007-01-01
Silapo EPOETIN ZETA Hospira UK Limited marketed Erythropoietin receptor 2007-01-01
Aranesp DARBEPOETIN ALFA Amgen marketed Erythropoiesis-stimulating Agent [EPC] Erythropoietin receptor 2001-01-01
Neorecormon EPOETIN BETA Roche Registration Limited marketed Erythropoietin receptor 1997-01-01
Epogen EPOETIN ALFA Amgen marketed Erythropoiesis-stimulating Agent Erythropoietin receptor 1989-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoiesis-stimulating agent (ESA) class)

  1. Amgen · 4 drugs in this class
  2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 3 drugs in this class
  3. Hospital de Clinicas de Porto Alegre · 2 drugs in this class
  4. Pfizer · 2 drugs in this class
  5. GlaxoSmithKline · 2 drugs in this class
  6. Chong Kun Dang Pharmaceutical · 2 drugs in this class
  7. Barts & The London NHS Trust · 1 drug in this class
  8. Australian and New Zealand Intensive Care Research Centre · 1 drug in this class
  9. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  10. Biocad · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epogen — Competitive Intelligence Brief. https://druglandscape.com/ci/retacrit. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: